157688-46-5

Basic information

• Product Name: 1-Boc-4-piperidylacetic acid
• Synonyms: N-TERT-BUTOXYCARBONYLPIPERIDINE-4-ACETIC ACID;N-TERT-BUTOXYCARBONYL-4-CARBOXYMETHYLPIPERIDINE;N-T-BUTOXYCARBONYLPIPERIDINE-4-ACETIC ACID;N-T-BUTOXYCARBONYL-4-PIPERIDYLACETIC ACID;N-T-BUTOXYCARBONYL-4-CARBOXYMETHYLPIPERIDINE;N-BOC-PIPERIDINYL-4-ACETIC ACID;N-BOC-4-PIPERIDINEACETIC ACID;RARECHEM EM WB 0085
• CAS NO: 157688-46-5
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: blocks;Carboxes;pharmacetical;Carboxylic Acids;Pyrans, Piperidines &Piperazines;Piperidine;Organic acids;Carboxylic Acids;Pyrans, Piperidines & Piperazines
• Mol File: 157688-46-5.mol

Chemical Properties

• Melting Point: 96-98°C
• Boiling Point: 373 °C at 760 mmHg
• Flash Point: 179.4 °C
• Appearance: Yellow to brown/Powder, Solid or Crystalline Powder
• Density: 1.121 g/cm³
• Vapor Pressure: 1.37E-06mmHg at 25°C
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 4.66±0.10(Predicted)
• BRN: 7028968
• CAS DataBase Reference: 1-Boc-4-piperidylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-piperidylacetic acid(157688-46-5)
• EPA Substance Registry System: 1-Boc-4-piperidylacetic acid(157688-46-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 157688-46-5(Hazardous Substances Data)

Usage

Chemical Properties

Solid

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-6-4-9(5-7-13)8-10(14)15/h9H,4-8H2,1-3H3,(H,14,15)/p-1

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 51052-78-9 4-piperidinylacetic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6622-91-9 2-(pyridine-4-yl)acetic acid hydrochloride 
• 144-55-8 sodium hydrogencarbonate 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 773837-37-9 sodium cyanide 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 55-22-1 pyridine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 41979-39-9 4-piperidone hydrochloride 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 161315-55-5 3-[2-(N-t-BOC-4-piperidinyl)-1-oxoethyl]-4(R)-(benzyl)-2-oxazolidinone 
• 416852-69-2 tert-butyl 4-{2-[methoxy(methyl)amino]-2-oxoethyl}piperidine-1-carboxylate 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 301232-40-6 4-((N-(4-(trifluoromethyl)benzyl)carbamoyl)methyl)-piperidine hydrochloride 
• 301185-09-1 3-(1-(t-Butoxycarbonyl)piperidin-4-yl)acetyl-4-(S)-benzyloxazolidin-2-one 
• 417721-95-0 tert-Butyl₄-(2-{[4-(4-amino-3-chlorophenoxy)-2-pyridyl]amino}-2-oxoethyl)-1-piperidinecarboxylate 
• 502482-53-3 C₂₇H₄₃N₃O₃ 
• 1143582-79-9 C₁₉H₂₇NO₄ 
• 718637-45-7 N-(4-methylthiophenyl)-1-tert-butoxycarbonylpiperidin-4-ylacetamide 
• 915762-21-9 tert-butyl 4-(2-oxo-2-[4-(([5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl)amino)piperidin-1-yl]ethyl)piperidine-1-carboxylate 

Relevant articles and documents

GLP-1R AGONISTS AND USES THEREOF

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

High-efficiency synthesis method of methyl 4-piperidineacetate

The invention discloses a high-efficiency synthesis method of methyl 4-piperidineacetate. The high-efficiency synthesis method comprises the following steps: firstly, preparing a colloid; secondly, taking titanium tetrachloride, di-n-octyl ether, cetylamine and carbon disulfide as raw materials to prepare reaction liquid; adding the reaction liquid into the colloid and dropwise adding ammonia water for precipitating to prepare a catalyst; taking 4-picolinic acid as a raw material and preparing 4-nipecotic acid under the reaction of the catalyst; taking the 4-nipecotic acid as the raw materialto prepare the methyl 4-piperidineacetate. The method has the advantages of simple operation, low preparation cost, high yield of a target product and easiness in separation.

NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION

Provided are a compound represented by formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic mixture, or prodrug thereof, and a preparation method thereof, and an application for preparing a pharmaceutical product for treating a disease related to obstructed airways, wherein each substituent in the compound represented by formula (I) is as described in the specification.

Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αiIbβ3

A series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their antiaggregative activity determined by Born's method was shown to be due to inhibition of fibrinogen binding to αIIbβ3. Molecular docking of RGD mimetics to αIIbβ3 receptor showed the key interactions in this complex, and also some correlations have been observed between values of biological activity and docking scores. The single crystal X-ray data were obtained for five mimetics.

Synthesis, biological evaluation and SAR studies of benzimidazole derivatives as H1-antihistamine agents

A series of benzimidazole derivatives have been designed, synthesized and evaluated for H1 antihistamine activity. Six compounds have showed potent antihistamine H1 activity. The primary SAR analysis indicated that benzyl or benzylidinyl substituted on the exo-nitrogen atom and C2 of the benzimidazole were significant. Further experiments indicated that compound 17d displayed excellent activity to reduce mast cell degranulation, moderate anti-PAF activity and decreased potency on hERG compared to astermizole. Hence compound 17d could serve as anti-allergic agent for further development.

Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl] cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors

A series of 4-amino cyclohexanes and 4-substituted piperidines were prepared and evaluated for inhibition of DPP-4. Analog 20q displayed both good DPP-4 potency and selectivity against other proteases, while derivative 20k displayed long half life and mod

The design and discovery of novel amide CCR5 antagonists

The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential.

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

BENZOFURAN DERIVATIVE

The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.